Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: A randomised controlled trial secondary analysis at 3 years

Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: A randomised controlled trial secondary analysis at 3 years

Saved in:

Bibliographic Details
Main Authors:	John E. Harris, Amit G. Pandya, Mark Lebwohl, Iltefat H. Hamzavi, Pearl Grimes, Alice B. Gottlieb, Howard L. Sofen, Angela Y. Moore, Mingyue Wang, Deanna Kornacki, Kathleen Butler, David Rosmarin
Format:	Article
Language:	English
Published:	Wiley 2024-12-01
Series:	Skin Health and Disease
Online Access:	https://doi.org/10.1002/ski2.404
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Phototherapy in vitiligo
by: Anuradha Bishnoi, et al.
Published: (2024-12-01)

Efficacy and Safety of Ruxolitinib Cream in Atopic Dermatitis Based on Previous Medication History
by: Andrew Blauvelt, et al.
Published: (2024-10-01)

Topical ruxolitinib for treatment-induced vitiligo in a patient with metastatic melanoma
by: Alpaslan Tasdogan, MD, PhD, et al.
Published: (2025-01-01)

Atopic Dermatitis Treatments Before and After Initiation of Ruxolitinib Cream: 6-Month Follow-Up Analysis of a US Payer Claims Database
by: Liu J, et al.
Published: (2025-02-01)

Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies
by: Eric L. Simpson, et al.
Published: (2024-12-01)

Vitiligo
by: Monisha Gupta
Published: (2024-12-01)

Ruxolitinib Associated Tuberculosis Presenting as a Neck Lump
by: Eamon Shamil, et al.
Published: (2015-01-01)

Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib
by: Maheen Z. Abidi, et al.
Published: (2016-01-01)

IN VIVO INOCULATION OF GBM CELLS IN RATS AND TREATMENT WITH RUXOLITINIB
by: Ioan-Alexandru Florian, et al.
Published: (2024-11-01)

Cord blood T regulatory cells synergize with ruxolitinib to improve GVHD outcomes
by: Ke Zeng, et al.
Published: (2024-12-01)

Advances in the etiopathogenesis of vitiligo
by: Thomas Mathew, et al.
Published: (2024-12-01)

Knowledge, attitude, and practice toward vitiligo among vitiligo patients: a mediation analysis
by: Hua Feng, et al.
Published: (2025-02-01)

The Implications of Liver Biopsy Results in Patients with Myeloproliferative Neoplasms Being Treated with Ruxolitinib
by: Douglas Tremblay, et al.
Published: (2019-01-01)

Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD
by: Philip T. Sobash, et al.
Published: (2020-01-01)

Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain
by: María Teresa Gómez-Casares, et al.
Published: (2017-11-01)

Melanosis with coincident vitiligo of the areola
by: Ramneek K. Dhami, et al.
Published: (2024-01-01)

Surgical modalities in the treatment of vitiligo
by: R. Vignesh Narayan, et al.
Published: (2024-12-01)

The role of camouflage in the treatment of vitiligo
by: Michelle Weaich
Published: (2024-12-01)

Repigmentation of Tenacious Vitiligo on Apremilast
by: Sara B. Huff, et al.
Published: (2017-01-01)

Study of thyroid disorders in vitiligo
by: Lalchamliani Khiangte, et al.
Published: (2023-04-01)

Safety and efficacy of combination therapy of interferon‐α2 and ruxolitinib in polycythemia vera and myelofibrosis
by: Stine Ulrik Mikkelsen, et al.
Published: (2018-08-01)

Research Progress on the Influence of Protein on Ice Cream Quality and Its Application in Ice Cream
by: Man LI, et al.
Published: (2024-12-01)

Vitiligo Review: etiopathogenesis, diagnosis and treatment
by: Aleksandra Witek, et al.
Published: (2025-01-01)

Vitiligo and cutaneous malignancy: what is the risk?
by: Sahngeun Jenny Mun, et al.
Published: (2024-12-01)

The Relationship between Perceived Stress and Vitiligo
by: M Tajvar, et al.
Published: (2024-03-01)

Vitiligo after Diphencyprone for Alopecia Areata
by: Mario Cezar Pires, et al.
Published: (2010-01-01)

Treatment advances in Vitiligo: An Updated Review
by: Ishrat Binti Ismail, et al.
Published: (2025-01-01)

Lichen Sclerosus Atrophicus with Vitiligo in Pediatrics
by: Juan Carlos Yanes Macías, et al.
Published: (2021-03-01)

Vitiligo: concomitant autoimmune and allergic diseases
by: Marcelina Kądziela, et al.
Published: (2024-02-01)

Vitiligo treatment: a literature review
by: Monika J. Leżanko, et al.
Published: (2025-01-01)

Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib
by: Keith L. Davis, et al.
Published: (2015-01-01)

Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE
by: Mi-Ae Lyu, et al.
Published: (2025-02-01)

Non-Melanoma Skin Cancer Aggravation in Polycythemia Vera: Triggered by Ruxolitinib and Silenced With an IFN/Cemiplimab
by: Efterpi Zafiriou, et al.
Published: (2025-01-01)

Life-Threatening Hypertriglyceridemia in a Patient on Ruxolitinib and Sirolimus for Chronic Graft-versus-Host Disease
by: Allison P. Watson, et al.
Published: (2018-01-01)

Management of pediatric steroid-refractory graft versus host disease: Challenges and outcome with ruxolitinib and etanercept
by: Sanjana Sarangarajan, et al.
Published: (2024-01-01)

Medical treatment of vitiligo: A narrative review
by: Anuradha Bishnoi, et al.
Published: (2024-12-01)

Outcome measures in vitiligo: A narrative review
by: K.B. Meghana, et al.
Published: (2024-12-01)

A Rare Colocalization of Lichen Planus and Vitiligo
by: David Veitch, et al.
Published: (2015-01-01)

Diphencyprone Induced Vitiligo: A Case Report
by: Mohammad Ali Nilforoushzadeh, et al.
Published: (2012-01-01)

Vitiligo: From mechanisms of disease to treatable pathways
by: Gaurav N. Pathak, et al.
Published: (2024-12-01)